Complejo Hospitalario Universitario De Ourense — Clinical Trial Site

66 Registered trials

26 Currently recruiting

Organisation

Complejo Hospitalario Universitario De Ourense

Location

Ourense, Spain

Identifier

ORG-100043872

Address

Calle De Ramon Puga Noguerol Nº 52, 32005, Spain

Departments

#760; Oncologia
1319: Hematología
7003; Oncology
7104: Hematologia
7108:Oncología
Anestesiología y Reanimación
Digestive
Digestivo
Gastroenterology
Hematologia
Hematology
Hospital Santa Maria Nai, Servicio Oncologia
Medical Oncology
N/A
Oncología
Oncology
Oncology Department
Servicio de digestivo
Servicio de Hematologia
Servicio de Oncologia
Servicio de Oncología Médica

Clinical trials at this site (66)

Search interface

Ursodeoxycolic acid for the prevention of relapsing complications after gallstone acute pancreatitis, a double-blind multicenter randomized-… Pending

2024-518237-28-00 recurrence of acute biliary pancreatitis 6
Moonlanding: A phase 2 study of pembrolizumab plus belzutifan, with or without lenvatinib, given before the main treatment for localized kid… Pending

2024-519673-18-00 Patients with localized renal cell carcinoma 4
Efficacy of the use of neoadjuvant with/without hyperthermic intraperitoneal chemotherapy in the treatment of locally advanced colon cancer Pending

2025-520471-29-00 Locally advanced adenocarcinoma of the colon and upper 5
A maintenance study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn’s disease Pending

2025-521037-86-00 Immune system diseases 5
A maintenance study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active ulcerative coliti… Pending

2025-521038-27-00 Immune system diseases 5
A biomarker enrichment trial of anti-EGFR agents in patients with advanced colorectal cancer (aCRC) with wild-type RAS and right primary tum… Pending

2025-521209-42-00 advanced colorectal cancer with wild-type RAS and right 6
Immunosuppressant Discontinuation in Elderly patients with ulcerative colitis And long-term remission Pending

2025-524675-23-00 Ulcerative Colitis 6
A Worldwide Study Testing the New Drug Lisaftoclax for Patients with Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma… Recruiting

2024-514084-26-00 Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymp 5 2025-08-22
Sotorasib combined with first-line chemotherapy for advanced pancreatic adenocarcinoma Recruiting

2024-516233-12-00 Advanced pancreatic adenocarcinoma 3 2025-08-08
Disitamab Vedotin with Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 Recruiting

2022-501105-12-00 Urothelial Carcinoma 5 2024-07-15
A trial to learn if odronextamab is safe and well-tolerated and how well it works compared to rituximab combined with different types of che… Recruiting

2022-502660-20-00 Follicular lymphoma 5 2024-01-23
A Study to Compare the Efficacy and Safety of Oral Azacitidine (Oral-Aza, ONUREG®) plus BSC versus Placebo plus BSC in Participants with IPS… Recruiting

2022-500479-29-00 International Prognostic Scoring System-Revised (IPSS-R 10 2023-03-28
Efficacy of Atenativ in Patients With Congenital Antithrombin Deficiency Undergoing Surgery or Delivery Recruiting

2024-515830-34-00 Congenital antithrombin deficiency 5 2023-02-14
LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib in RET fusion-Positive NSCLC Recruiting

2023-506784-33-00 RET fusion-Positive NSCLC 5 2021-01-19
An induction study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn's Disease Recruiting

2025-521036-11-00 Immune system disseases 5 2026-03-23
An induction study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Ulcerative Colitis Recruiting

2025-521035-37-00 Immune system diseases 5 2026-03-02
A Phase 2 Randomized Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab Adizutecan in Combination with Fluorouracil, … Recruiting

2024-513008-32-00 Adenocarcinoma of the gastroesophageal junction 4 2025-12-17
ENGIC 06 (PRODIGE 114) – FFCD 2401 – FRUQUITAS Randomized phase III trial to compare trifluridine/tipiracil + Fruquintinib versus triflurid… Recruiting

2025-522395-92-00 metastatic oeso-gastric adenocarcinoma 5 2025-12-15
Phase II study of tarlatamab as a follow-up treatment after chemo and radiation in patients with small cell lung cancer (SCLC) who cannot re… Recruiting

2024-515201-26-00 Small cell lung cancer (SCLC) 4 2025-12-09
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis Recruiting

2025-521242-26-00 Moderately to Severely Active Ulcerative Colitis 4 2025-11-27
A Phase 2 Study of Momelotinib in Participants with low-risk myelodysplastic syndrome Recruiting

2024-519928-24-00 Myelodysplastic Syndrome 4 2025-08-21
A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esoph… Recruiting

2023-509630-19-00 Esophageal Squamous Cell Carcinoma (ESCC) 5 2025-07-31
A trial comparing the treatment of rilvegostomig with fluoropyrimidine and trastuzumab deruxtecan to the standard treatment in patients with… Recruiting

2024-512583-57-00 HER2-positive locally advanced or metastatic gastric or 5 2025-07-30
A study to evaluate the efficacy of APG-2575 (Lisaftoclax) plus azacitidine (AZA) vs. placebo plus AZA in newly diagnosed adult subjects wit… Recruiting

2024-517247-31-00 Newly Diagnosed Higher Risk Myelodysplastic Syndrome 5 2025-07-07